Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract #3227: Development of new clinically-relevant human melanoma xenograft models

Véronique Mathieu, christine pirker, Jean-François Gaussin, Mischael Dehoux, Robert kiss and walter berger
Véronique Mathieu
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
christine pirker
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-François Gaussin
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mischael Dehoux
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert kiss
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
walter berger
Free University of Brussels, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; Unibioscreen SA, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Melanomas whose incidence is still increasing, remain associated with dismal prognosis given their inherent resistance to apoptosis and their strong propensity to metastasize, notably to the lungs, liver and brain. Metastatic melanoma patients have only limited treatment options consisting of mono- or poly-therapy with dacarbazine (DTIC), cisplatin and temozolomide (TMZ). These produce only marginal clinical improvements and have no substantial impact on overall patient survival. Even biological/immuno-therapy has not contributed greater clinical benefits than DTIC alone. In order to test and develop new therapeutic options, greater attention needs to be paid to the clinical relevance of the animal model used. Numerous agents/regimens have shown really promising activity in existing pre-clinical melanoma models but efficacy could then not be demonstrated in clinical trials. Therefore our aim was to establish more reliable in vivo models through i) isolation of melanoma cells from primary and metastatic lesions, ii) in vitro characterization of their genomic (array CGH, p53 mutations) and biological properties (growth, migration, sensitivity to cytotoxic agents, expression of drug resistance and anti-apoptotic proteins) and iii) their grafting either s.c., i.v. or orthotopically into their site of origin in nude mice and when relevant follow up with histological analysis, determination of their drug sensitivity and comparison of their responses to those of established melanoma models. 35 primary melanoma cell lines have been established and to date 10 have been further characterized. In vitro these primary cultures have been found to be equally poorly sensitive to chemotherapy as established melanoma cell lines. However with primary cultures, tumor \#8220;take\#8221; and metastases were increased compared to those of established cell lines (notably spontaneous lung metastases achieved in 100% (VM-21 grafted) and 70% (VM-1) of mice). Furthermore, after the excision of primary tumors, micro-metastases in lungs were found to lead to animal death. No response to DTIC, TMZ and/or cisplatin either in terms of tumor growth or animal survival could be achieved in these new models, while the widely used B16F10 mouse model is generally drug-responsive. Furthermore, i.v. injection of these primary cells did not lead to metastases indicating that this is not an appropriate method to study melanoma metastatic processes. In contrast, we have developed two brain metastatic models through direct implantation of human brain metastases-derived melanoma cells into the brains of mice. These models are characterized by massive invasion of normal brain tissue and resistance to chemotherapy. In conclusion, in vivo models developed with primary melanoma cultures may be of greater relevance than those using established cell lines because the course of the disease and the chemotherapeutic response more closely resemble the clinical situation in humans.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3227.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #3227: Development of new clinically-relevant human melanoma xenograft models
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #3227: Development of new clinically-relevant human melanoma xenograft models
Véronique Mathieu, christine pirker, Jean-François Gaussin, Mischael Dehoux, Robert kiss and walter berger
Cancer Res May 1 2009 (69) (9 Supplement) 3227;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #3227: Development of new clinically-relevant human melanoma xenograft models
Véronique Mathieu, christine pirker, Jean-François Gaussin, Mischael Dehoux, Robert kiss and walter berger
Cancer Res May 1 2009 (69) (9 Supplement) 3227;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
Show more 3

Tools for Discovery -- Poster Presentations - Proffered Abstracts

  • Abstract #3223: Efficient generation of primary xenografts using normal and malignant human mammary epithelium in SCID/Beige mice without humanizing fibroblasts
  • Abstract #3224: Development and characterization of a panel of human uveal melanoma xenografts established from primary and/or metastatic patient\#8217;s tumors
  • Abstract #3229: Combined ultrasound and fluorescence imaging for monitoring tumors in an orthotopic mouse model of pancreatic cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement